Ophthotech Corp. (OPHT) announced Monday morning that its two Phase 3 clinical trials of Fovista anti-PDGF therapy in combination with Lucentis failed to meet their primary endpoints. The drug was being developed as a treatment for wet age-related macular degeneration.
from RTT - Before the Bell http://ift.tt/2hqcnTW
via IFTTT
No comments:
Post a Comment